Bausch Health Companies Stock News

Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.

Bausch Health Companies Inc (NYSE:BHC) just said that its eye-care products unit Bausch + Lomb filed to go public on Thursday on both U.S. and Canadian exchanges via an initial public offering (IPO).

Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would spin off the eye-care company. The com

Bausch Health Companies (BHC) files registration statement in the already announced move to spin-off its eye health business, Bausch + Lomb, for it to trade as a separate public

Bausch & Lomb Corp. has filed for an initial public offering, according to a filing late Thursday. The Bausch Health Cos. Inc. subsidiary seeks to sell up to $100 million worth of shares, although that''s often a placeholder amount used to calculate filing fees. Bausch Health said in August 2020 it planned to spin off Bausch & Lomb, which mostly makes eye-health products. Bausch Health would remain majority owner of the new public company. Bausch & Lomb plans to list its shares on the New York Stock Exchange and the Toronto Stock Exchange under the symbol BLCO. Bausch & Lomb listed earnings of $131 million at the end of September, compared with $191 million at the end of September 2020. Sales rose to $2.8 billion in the nine months to Sept. 30, from $2.5 billion in the same period in 2020. Bausch Health changed its name from Valeant in 2018 following allegations of accounting improprieties and price gouging. . Bausch Health, then Valeant, bought the old Bausch + Lomb, which traded from December 1958 to October 2007 on the NYSE, in 2013.

Bausch & Lomb Corp. has filed for an initial public offering, according to a filing late Thursday. The Bausch Health Cos.

Bausch Health Companies, Inc. (BHC) CEO Joe Papa at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

While we do not violate our overall cost basis lightly, we do believe the weakness thus far in 2022 is presenting an opportunity that we want to take advantage.

Bausch has reduced net debt by some $5 billion since the worst of the turmoil in 2017. This makes a dent in leverage, certainly as the underlying business has stabilized.

Bausch Health Companies Inc. ( BHC , Financial) has traded in a low range for years, but that could soon change. The company is making progress on its research and recently announced a collaboration w

Appearing on CNBC''s "Halftime Report," Jim Cramer explained why Chevron, Eli Lilly, Honeywell and Bausch Health are some of his favorite stocks for the new year.

Host of Mad Money Jim Cramer joins the investment committee on 'Halftime Report' to discuss his top stock picks as well as his analysis on IBM, Wynn Resorts and more.

CNBC Television published this video item, entitled Bulls Read more